Article
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Antiviral research - 1 Sept 2013
Lawitz Eric, Sulkowski Mark, Jacobson Ira, Kraft Walter K, Maliakkal Benedict, Al-Ibrahim Mohamed, Gordon Stuart C, Kwo Paul, Rockstroh Juergen Kurt, Panorchan Paul, Miller Michelle, Caro Luzelena, Barnard Richard, Hwang Peggy May, Gress Jacqueline, Quirk Erin, Mobashery Niloufar
Abstract excerpt
Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vaniprevir monotherapy in patients with genotype 1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.